Month: April 2017

Durban – Media reports that the Competition Commission has decided to take up the Democratic Alliance’s request to investigate the alleged anti-competitive conduct of Aspen Pharmacare (“Aspen”) in South Africa, in its preliminary investigation into the pharmaceutical sector, has reference. Aspen welcomes the process and the opportunity to categorically set aside such allegations of anti-competitive… Continue reading Aspen’s response to the reported Competition Commission investigation

In reference to the articles reported in the European press on 14 and 15 April 2017, Aspen Pharmacare Holdings Limited (“Aspen”) has the following comments: Aspen has clearly demonstrated its commitment to providing quality medicines affordably over many years. The supply of the oncology products in question is no exception. Aspen’s status as a responsible… Continue reading Statement in response to press reports of 14 and 15 April 2017